[Home](/)/[Resources](/resources)/US FDA Combination Products USMedical devicesRegulation guide # US FDA Combination Products A product that combines a drug, biologic, or device — an injector with a pre-filled drug cartridge, a drug-eluting implant, a wearable that also delivers a therapeutic — does not automatically fall into one FDA review track. Combination products get their own jurisdiction and classification process, and getting it wrong at the start can send your submission to the wrong FDA center entirely. Copy Link[Share on WhatsApp](https://wa.me/?text=https%3A%2F%2Fkrono-labs.com%2Fguides%2Fus-combination-products-fda) At a glance Coordinating office FDA Office of Combination Products (OCP) Statutory basis 21 CFR Part 3 Common combos Drug-device, biologic-device, drug-biologic-device Key decision Primary Mode of Action (PMOA) Tool Request for Designation (RFD) ## What makes a product a "combination product" ### The four regulatory categories FDA defines a combination product as a single entity combining two or more regulated components (drug/device, biologic/device, drug/biologic, or drug/device/biologic); two or more separately packaged products intended for use together; or a product packaged separately but labeled for use only with another specific product to achieve the intended use. ### Examples in hardware-adjacent categories Prefilled drug-delivery pens and autoinjectors, drug-eluting stents, wearable devices that also deliver a therapeutic agent, and diagnostic-plus-companion-therapeutic pairings are all common combination product structures. ### Why this matters for a hardware company A hardware team that adds a therapeutic-delivery function to a device — even a seemingly incidental one — can shift the entire product into combination-product jurisdiction, with a materially different review process than a device-only submission. ## How FDA assigns the lead center ### Primary Mode of Action (PMOA) FDA determines which regulated component provides the most important therapeutic action of the combination product — the PMOA — and assigns the product to the FDA center that regulates that type of product (CDER for drugs, CBER for biologics, CDRH for devices) as the lead reviewer. ### Request for Designation (RFD) When jurisdiction is unclear, a sponsor can submit a formal Request for Designation to the Office of Combination Products, which issues a binding determination of the lead center and applicable regulatory pathway within a statutory timeframe. ### Consulting center involvement Even after a lead center is assigned, other centers with relevant expertise are typically consulted during review — a device-led combination product involving a drug still gets meaningful CDER input on the drug component, and vice versa. ## Planning a combination product submission 01 Identify every regulated component in your product early — a drug reservoir, a biologic coating, or a device delivery mechanism can each trigger combination product status on its own. 02 Assess the Primary Mode of Action honestly; misjudging which component drives the therapeutic effect leads to submitting to the wrong center and losing review time. 03 File a Request for Designation with the Office of Combination Products if jurisdiction is genuinely ambiguous — this is faster and more reliable than guessing and risking a rejection at intake. 04 Build your quality system to satisfy both applicable device Quality System Regulation elements and, where relevant, current Good Manufacturing Practice expectations for the drug or biologic component. 05 Plan review timelines around the lead center’s typical pathway (510(k)/PMA-style device review vs. NDA/BLA-style drug or biologic review), since combination products often take longer than either component alone. ## Frequently asked questions ### What is the Primary Mode of Action and why does it matter so much? The Primary Mode of Action (PMOA) is the single most important therapeutic action among a combination product’s regulated components. It determines which FDA center leads the review — and because CDER, CBER, and CDRH each apply different regulatory frameworks and review timelines, the PMOA determination effectively decides the shape of your entire submission strategy. ### When should I file a Request for Designation? File an RFD when you genuinely cannot determine, with reasonable confidence, which FDA center has jurisdiction or what the correct regulatory pathway is. The Office of Combination Products issues a binding determination, which removes the risk of submitting to the wrong center and having your application rejected or delayed at intake. ### Does adding a drug-delivery function to my device always trigger combination product status? Generally yes, if the added function meets FDA’s combination product definition — even a function that seems secondary to the device’s main use can create combination product status once a regulated drug or biologic component is genuinely present and intended for use with the device. ### Do combination products need to satisfy both device and drug quality requirements? Yes, typically. Combination products are generally expected to comply with quality system requirements appropriate to each constituent part — device Quality System Regulation elements for the device component and current Good Manufacturing Practice expectations for the drug or biologic component — under FDA’s combination product current Good Manufacturing Practice regulations. **Disclaimer:** This page is an educational resource only and does not constitute legal or regulatory advice. Combination product jurisdiction determinations are fact-specific and can be complex — consult the FDA Office of Combination Products guidance and qualified regulatory counsel before finalizing a submission strategy. 🇺🇸 US roadmap for your product Every standard, document, and test that applies — free, no account required. See your free roadmap[ Want an expert to take your product through 🇺🇸 US compliance for you? One consultant from Krono's compliance team takes your product from requirements to legal sale, with a fixed quote before any work starts. See compliance services](/services) Learn this properly In-depth course that teaches the full process, not just this one answer. [Start the course — $199](/courses/17-fda-medical-device-registration-510k-hardware-startups)[Prefer to read? Get the book — $24.99](/books/17-fda-medical-device-registration-510k-hardware-startups) Related guides * [US Software as a Medical Device (SaMD)When software qualifies as a medical device, and the 510(k), De Novo, and PMA pathway decision.](/guides/us-samd-software-medical-device) * [FDA Medical Device RegulationComplete guide to FDA medical device regulation.](/guides/fda-medical-device-regulation) * [US PMA Premarket ApprovalComplete guide to US PMA premarket approval.](/guides/us-pma-premarket-approval) * [US Quality System RegulationComplete guide to US Quality System Regulation.](/guides/us-quality-system-regulation)